Myosteatosis Predicts Poor Prognosis in Patients With Castration‐Resistant Prostate Cancer Treated With Enzalutamide
International Journal of Urology · 2026-05 · 33 (5)
DOI: 10.1111/iju.70476 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, online erschienen am 29.04.2026. Verfasst von Tomohiro Kanaki und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The University of Osaka Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Benzamides, Nitriles, Phenylthiohydantoin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Prostate cancer prognostication has traditionally emphasized tumor‐related factors (e.g., Gleason score and metastatic burden). Emerging evidence suggests that physical (host) factors influence outcomes. This study evaluated whether physical factors, including myosteatosis and sarcopenia, are prognostic factors in patients with androgen receptor signaling inhibitor‐naïve, castration‐resistant prostate cancer.
Methods
We retrospectively analyzed 117 androgen receptor signaling inhibitor‐naïve patients with castration‐resistant prostate cancer who received enzalutamide treatment at The University of Osaka Hospital between 2014 and 2024. Myosteatosis and sarcopenia were derived from pretreatment abdominal computed tomography. The primary endpoint was failure‐free survival. Multivariate Cox proportional hazards analysis was performed to identify independent prognostic factors.
Results
Myosteatosis and sarcopenia were present in 49 (42%) and 46 (39%) patients, respectively. In univariate analyses, the Charlson comorbidity index, body mass index, and sarcopenia demonstrated no significant association with failure‐free survival, whereas myosteatosis and distant metastasis were associated with a shorter failure‐free survival. In multivariable analysis, myosteatosis remained an independent predictor of shorter failure‐free survival (hazard ratio 1.91, 95% confidence interval 1.22–2.99, p < 0.01). The median failure‐free survival was 6 and 17 months with and without myosteatosis, respectively ( p < 0.01).
Conclusions
Myosteatosis is an independent failure‐free survival predictor in patients with androgen receptor signaling inhibitor‐naïve castration‐resistant prostate cancer treated with enzalutamide. Computed tomography‐based evaluation of muscle quality may be useful for predicting the outcome of androgen receptor signaling inhibitors in patients with castration‐resistant prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The University of Osaka Graduate School of Medicine, Osaka, Japan.
ORCID-Profile: Koji Hatano, Yohei Okuda, Yoshiyuki Yamamoto, Atsunari Kawashima
Zitieren
APA
Kanaki, T., Hatano, K., Oka, T., Tani, M., Konishi, M., Liu, Y., Horitani, H., Matsukawa, A., Inoguchi, S., Yoshimura, A., Horibe, Y., Sassi, N., Okuda, Y., Ishizuya, Y., Hayashi, T., Yamamoto, Y., Kato, T., Kawashima, A., & Nonomura, N. (2026). Myosteatosis Predicts Poor Prognosis in Patients With Castration‐Resistant Prostate Cancer Treated With Enzalutamide. International Journal of Urology, 33(5). https://doi.org/10.1111/iju.70476
Vancouver
Kanaki T, Hatano K, Oka T, Tani M, Konishi M, Liu Y, et al. Myosteatosis Predicts Poor Prognosis in Patients With Castration‐Resistant Prostate Cancer Treated With Enzalutamide. International Journal of Urology. 2026;33(5). doi:10.1111/iju.70476
BibTeX
@article{Kanaki2026,
author = {Kanaki, Tomohiro and Hatano, Koji and Oka, Toshiki and Tani, Masaru and Konishi, Masatoshi and Liu, Yutong and Horitani, Hiromu and Matsukawa, Atsuki and Inoguchi, Shunsuke and Yoshimura, Akihiro and Horibe, Yuki and Sassi, Nesrine and Okuda, Yohei and Ishizuya, Yu and Hayashi, Takuji and Yamamoto, Yoshiyuki and Kato, Taigo and Kawashima, Atsunari and Nonomura, Norio},
title = {Myosteatosis Predicts Poor Prognosis in Patients With Castration‐Resistant Prostate Cancer Treated With Enzalutamide},
journal = {International Journal of Urology},
year = {2026},
volume = {33},
number = {5},
doi = {10.1111/iju.70476}
}
EUVIMED